과제정보
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (RS-2023-00239222).
참고문헌
- Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397(10290):2212-24. https://doi.org/10.1016/S0140-6736(20)32511-3
- Bacon BR, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107(4):1103-9. https://doi.org/10.1016/0016-5085(94)90235-6
- Khan RS, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology 2019;70(2):711-24. https://doi.org/10.1002/hep.30429
- Yang KC, et al. Association of non-alcoholic fatty liver disease with metabolic syndrome independently of central obesity and insulin resistance. Sci Rep 2016;6:27034.
- Iacob SA, Iacob DG. Non-alcoholic fatty liver disease in HIV/HBV patients - a metabolic imbalance aggravated by antiretroviral therapy and perpetuated by the hepatokine/adipokine Axis breakdown. Front Endocrinol (Lausanne) 2022;13:814209.
- Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol 2015;13(12):2062-70. https://doi.org/10.1016/j.cgh.2015.07.029
- Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology 2016;150(8):1769-77. https://doi.org/10.1053/j.gastro.2016.02.066
- Zheng Q, et al. Comparison of animal models for the study of nonalcoholic fatty liver disease. Lab Invest 2023;103(7):100129.
- Jadhav K, Cohen TS. Can you trust your gut? Implicating a disrupted intestinal microbiome in the progression of NAFLD/NASH. Front Endocrinol (Lausanne) 2020;11:592157.
- Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009;7(3):293-302. https://doi.org/10.2174/157016109788340767
- Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58(11):1685-93. https://doi.org/10.1016/S0006-2952(99)00212-9
- Ratan ZA, et al. Pharmacological potential of ginseng and its major component ginsenosides. J Ginseng Res 2021;45(2):199-210. https://doi.org/10.1016/j.jgr.2020.02.004
- Zhao F, Lu M, Wang H. Ginsenoside Rg1 ameliorates chronic intermittent hypoxia-induced vascular endothelial dysfunction by suppressing the formation of mitochondrial reactive oxygen species through the calpain-1 pathway. J Ginseng Res 2023;47(1):144-54. https://doi.org/10.1016/j.jgr.2022.07.006
- Cho HJ, Kim E, Yi YS. Korean red ginseng saponins play an anti-inflammatory role by targeting caspase-11 non-canonical inflammasome in macrophages. Int J Mol Sci 2023;24(2).
- Yi YS. Potential benefits of ginseng against COVID-19 by targeting inflammasomes. J Ginseng Res 2022;46(6):722-30. https://doi.org/10.1016/j.jgr.2022.03.008
- Min JH, Cho HJ, Yi YS. A novel mechanism of Korean Red Ginseng-mediated anti-inflammatory action via targeting caspase-11 non-canonical inflammasome in macrophages. J Ginseng Res 2022;46(5):675-82. https://doi.org/10.1016/j.jgr.2021.12.009
- Yi YS. New mechanisms of ginseng saponin-mediated anti-inflammatory action via targeting canonical inflammasome signaling pathways. J Ethnopharmacol 2021;278:114292.
- Huang Q, et al. Review of ginsenosides targeting mitochondrial function to treat multiple disorders: current status and perspectives. J Ginseng Res 2021;45(3):371-9. https://doi.org/10.1016/j.jgr.2020.12.004
- Shi ZY, Zeng JZ, Wong AST. Chemical structures and pharmacological profiles of ginseng saponins. Molecules 2019;24(13).
- Nguyen NH, Nguyen CT. Pharmacological effects of ginseng on infectious diseases. Inflammopharmacology 2019;27(5):871-83. https://doi.org/10.1007/s10787-019-00630-4
- Li Z, Ji GE. Ginseng and obesity. J Ginseng Res 2018;42(1):1-8. https://doi.org/10.1016/j.jgr.2016.12.005
- Aminifard T, Razavi BM, Hosseinzadeh H. The effects of ginseng on the metabolic syndrome: an updated review. Food Sci Nutr 2021;9(9):5293-311. https://doi.org/10.1002/fsn3.2475
- Hong SH, et al. Anti-oxidant and natural killer cell activity of Korean red ginseng (Panax ginseng) and urushiol (Rhus vernicifera Stokes) on non-alcoholic fatty liver disease of rat. Food Chem Toxicol 2013;55:586-91. https://doi.org/10.1016/j.fct.2013.01.022
- Bahr I, et al. Obesity-associated alterations of natural killer cells and immunosurveillance of cancer. Front Immunol 2020;11:245.
- Hong JT, et al. Effect of Korea red ginseng on nonalcoholic fatty liver disease: an association of gut microbiota with liver function. J Ginseng Res 2021;45(2):316-24. https://doi.org/10.1016/j.jgr.2020.07.004
- Xu Y, et al. Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease. Hepatol Int 2021;15(2):350-65. https://doi.org/10.1007/s12072-021-10138-1
- Park M, et al. Ameliorative effects of black ginseng on nonalcoholic fatty liver disease in free fatty acid-induced HepG2 cells and high-fat/high-fructose diet-fed mice. J Ginseng Res 2020;44(2):350-61. https://doi.org/10.1016/j.jgr.2019.09.004
- Wang F, et al. Ginseng saponin enriched in Rh1 and Rg2 ameliorates nonalcoholic fatty liver disease by inhibiting inflammasome activation. Nutrients 2021;13(3).
- Choi SY, et al. Fermented Korean red ginseng extract enriched in Rd and Rg3 protects against non-alcoholic fatty liver disease through regulation of mTORC1. Nutrients 2019;11(12).
- Li G, et al. Ginsenoside Rg1 exerts anti-apoptotic effects on non-alcoholic fatty liver cells by downregulating the expression of SGPL1. Mol Med Rep 2022;25(5).
- Gu D, et al. Transcriptome analysis reveals the efficacy of ginsenoside-Rg1 in the treatment of nonalcoholic fatty liver disease. Life Sci 2021;267:118986.
- Qi R, et al. Ginsenoside Rg1 protects against d-galactose induced fatty liver disease in a mouse model via FOXO1 transcriptional factor. Life Sci 2020;254:117776.
- Xu Y, et al. Ginsenoside Rg1 protects against non-alcoholic fatty liver disease by ameliorating lipid peroxidation, endoplasmic reticulum stress, and inflammasome activation. Biol Pharm Bull 2018;41(11):1638-44. https://doi.org/10.1248/bpb.b18-00132
- Lee SM, et al. Characterization of Korean red ginseng (Panax ginseng meyer): history, preparation method, and chemical composition. J Ginseng Res 2015;39(4):384-91. https://doi.org/10.1016/j.jgr.2015.04.009
- Jiang S, et al. Peroxisomal fitness: a potential protective mechanism of fenofibrate against high fat diet-induced non-alcoholic fatty liver disease in mice. Diabetes Metab J 2022;46(6):829-42.
- Kim MS, et al. Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes. Liver Int 2013;33(10):1583-93. https://doi.org/10.1111/liv.12287
- Chen XJ, et al. Ameliorative effects of Compound K and ginsenoside Rh1 on nonalcoholic fatty liver disease in rats. Sci Rep 2017;7:41144.
- Piao X, et al. Advances in saponin diversity of Panax ginseng. Molecules 2020;25(15).
- Huang Q, et al. Ginsenoside Rb2 alleviates hepatic lipid accumulation by restoring autophagy via induction of Sirt1 and activation of AMPK. Int J Mol Sci 2017;18(5).
- Liu CY, et al. Preparation of minor ginsenosides C-Mc, C-Y, F2, and C-K from American ginseng PPD-ginsenoside using special ginsenosidase type-I from Aspergillus Niger g.848. J Ginseng Res 2015;39(3):221-9. https://doi.org/10.1016/j.jgr.2014.12.003
- Roh E, et al. Ginsenoside Mc1 improves liver steatosis and insulin resistance by attenuating ER stress. J Ethnopharmacol 2020;259:112927.
- Jeong H, et al. Beneficial effects of Korean red ginseng in the progression of nonalcoholic steatohepatitis via FABP4 modulation. Am J Chin Med 2018:1-27.
- Yang D, et al. Oral administration of Jinan Red Ginseng and licorice extract mixtures ameliorates nonalcoholic steatohepatitis by modulating lipogenesis. J Ginseng Res 2022;46(1):126-37. https://doi.org/10.1016/j.jgr.2021.05.006
- Wei W, et al. Black ginseng protects against Western diet-induced nonalcoholic steatohepatitis by modulating the TLR4/NF-kappaB signaling pathway in mice. J Food Biochem 2022;46(12):e14432.
- Choi N, et al. Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model. J Ginseng Res 2019;43(2):196-208. https://doi.org/10.1016/j.jgr.2017.10.002
- Lu B, et al. 20(S)-Protopanaxatriol ameliorates MAFLD by inhibiting NLRP3 inflammasome. Eur J Pharmacol 2023;940:175468.
- Hyun SH, et al. Physiological and pharmacological features of the non-saponin components in Korean Red Ginseng. J Ginseng Res 2020;44(4):527-37. https://doi.org/10.1016/j.jgr.2020.01.005
- Christensen LP. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 2009;55:1-99.